Clinical trials: HPV InfectioN
Warts, Warts Hand
CellFX System for the Treatment of Cutaneous Non-Genital Warts
This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.
- Conditions
- Warts, Warts Hand, Verruca
- Trial name
- NCT04554394
- Testing
- CellFX Device
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pulse Biosciences, Inc.
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV).
- Trial name
- NCT05120869
- Testing
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Where
- 2 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years…
- Trial name
- NCT00877877
- Testing
- Blood sampling
- Where
- 26 sites in Colombia, Germany and 3 more
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human papillomavirus (HPV) is a member of the Papillomaviridae family of DNA viruses that is capable of infecting humans. HPV infection can cause cancers of the cervix, vulva, vagina, and anus in women or cancers of the anus and…
- Trial name
- TRAP-HPV (NCT01824537)
- Testing
- HPV vaccine, Gardasil 9, Hepatitis A vaccine
- Where
- Canada
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- McGill University
Human Papillomavirus
Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men
Studies indicate that men who have sex with men (MSM) have a high prevalence of anogenital Human papillomavirus (HPV) infection and increased risk for HPV related anogenital lesions including anogenital warts, anal…
- Trial name
- HYPER (NCT01422356)
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Alfred
Healthy Adult Female Participants, Prevention
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
This study was conducted to assess the safety, immunogenicity, efficacy and long-term effectiveness of a vaccine being evaluated for the prevention of human papillomavirus (HPV) infection and disease in mid-adult women.
- Conditions
- Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Trial name
- NCT00090220
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,819 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer.
- Trial name
- NCT01461096
- Testing
- Quadrivalent HPV Vaccine
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 575 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Common Wart
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
- Trial name
- NCT03812510
- Testing
- A-101
- Where
- 46 sites in United States
- Volunteers
- 426 people
- Sponsor
- Aclaris Therapeutics, Inc.
Warts
Intralesional Vitamin D Injection for Treatment of Common Warts
Researchers are trying to find out if injecting Vitamin D into a wart is an effective treatment.
- Trial name
- NCT04278573
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Stephen P. Merry
Human Papillomavirus Infection
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)
This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.
- Trial name
- NCT01078220
- Volunteers
- 189,629 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00423046
- Testing
- GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc)
- Where
- 40 sites in United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Condylomata Acuminata, Papillomavirus Infections
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious
- Trial name
- CARE-1 (NCT03981822)
- Testing
- VP-102 and applicator
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus…
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive
- Trial name
- NCT03603808
- Testing
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- AIDS Malignancy Consortium
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
Common Warts
A Study of A-101 Solution in Subjects With Common Warts.
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
- Trial name
- NCT02669862
- Testing
- A-101 Solution 40, A-101 Solution 45, Vehicle Solution
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aclaris Therapeutics, Inc.